期刊
IMMUNITY
卷 18, 期 1, 页码 1-6出版社
CELL PRESS
DOI: 10.1016/S1074-7613(02)00502-2
关键词
-
类别
资金
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069929, R01HL072412] Funding Source: NIH RePORTER
- NHLBI NIH HHS [HL 72412, HL 69929] Funding Source: Medline
The TNF-related apoptosis-inducing ligand (TRAIL) offers great promise as a cancer therapeutic. Initially, soluble recombinant versions of the TRAIL molecule have exhibited specific tumoricidal activity against a variety of tumors alone, or in combination with other cancer treatments, and much anticipation awaits the outcomes from early clinical trials. More recently, the natural role of TRAIL has been explored in tumor and allogeneic bone marrow transplantation models in the mouse. Strikingly, the TRAIL effector pathway appears a vital component of immunosurveillance of spontaneous or resident tumor cells by both T cells and NK cells, stimulating more hope that manipulating TRAIL activity is a natural path to improved cancer immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据